Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms Review article
Article Sidebar
Published:
Mar 31, 2021
Keywords:
BPO, LUTS, overactive bladder, tamsulosin, combination therapy
Main Article Content
Abstract
Men with lower urinary tract symptoms (LUTS) treated with α-blockers may experience overactive bladder (OAB) symptoms and receive antimuscarinic drugs. Mirabegron (B3-adrenoreceptor agonist) is an alternative add-on therapy, that has been shown to be more effective than placebo in improving OAB symptoms. Superior results observed for tamsulosin plus mirabegron in mean volume voided per micturition, urgency episodes per day, and total urgency and frequency score. Higher rates of drug related treatment emergent adverse events were noted with tamsulosin plus mirabegron. The results of PLUS reveal the utility of mirabegron and tamsulosin therapy in the treatment of men with benign prostatic hyperplasia who developed symptoms of overactive bladder. The MATCH study confirmed that combination therapy for 12 weeks in men with symptoms of LUTS and OAB was more effective than placebo and was well tolerated.
Article Details
How to Cite
Wiatr , T., & Chłosta , P. (2021). Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms. Medycyna Faktow (J EBM), 14(1(50), 58-62. https://doi.org/10.24292/01.MF.0121.7
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21(2): 167-78.
2. Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014; 33(5): 622-4.
3. Coyne KS, Sexton CC, Vats V et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011; 77: 1081.
4. Irwin DE, Kopp ZS, Agatep B et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011; 108: 1132.
5. Chapple CR, Dvorak V, Radziszewski P et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013; 24(9): 1447-58.
6. Chapple C. Systematic review of therapy for men with overactive bladder. Can Urol Assoc J. 2011; 5(suppl 2): S143-5.
7. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016; 43: 289.
8. Fourcade RO, Lacoin F, Roupret M et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol. 2012; 30: 419.
9. McVary KT, Roehrborn CG, Avins AL et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185: 1793.
10. Kaplan SA, Roehrborn CG, Dmochowski R et al. Tolterodine extended release improves over- active bladder symptoms in men with overactive bladder and nocturia. Urology. 2006; 68: 328.
11. Chancellor MB, Zinner N, Whitmore K et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther. 2008; 30: 1766.
12. van Kerrebroeck P, Chapple C, Drogendijk T et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013; 64: 1003.
13. Chapple C, Herschorn S, Abrams P et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with a-blockers. Eur Urol. 2009; 56: 534.
14. Chapple CR, Khullar V, Gabriel Z et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008; 54: 543.
15. Kakizaki H, Lee KS, Yamamoto O et al. Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH). Eur Urol Focus. 2019; 6(4): P729-37.https://doi.org/10.1016/j.euf.2019.10.019.
16. Roehrborn CG. Chapter 103: Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History. In: Wein AJ, Kavoussi LR, Partin AW et al (ed). Campbell and Walsh Urology, 11th Edition. Elsevier-Saunders, Philadephia, PA: 2435.
17. Levin RM, Monson FC, Haugaard N et al. Genetic and cellular characteristics of bladder outlet obstruction. Urol Clin North Am. 1995; 22: 263-83.
18. Levin RM, Haugaard N, O’Connor L et al. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn. 2000; 19: 609-29.
19. Nordling J. The aging bladder – a significant but underestimated role in the development of lower urinary tract symptoms. Exp Gerontol. 2002; 37: 991-9.
20. Chai TC, Andersson KE, Tuttle JB et al. Altered neural control of micturition in the aged f344 rat. Urol Res. 2000; 28: 348-54.
21. Van Venrooj GE, Van Melick HH, Eckhardt MD et al. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol. 2002; 168: 605-9.
22. Wada N, Iuchi H, Kita M et al. Urodynamic efficacy and safety of mirabegron add-on treatment with tamsulosin for Japanese male patients with overactive bladder. Low Urin Tract Symptoms. 2016; 8: 171-6.
23. Ichihara K, Masumori N, Fukuta F et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015; 193: 921-6.
24. Yamaguchi O, Kakizaki H, Homma Y et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms – ASSIST, randomized controlled study. Urology. 2011; 78: 126-33.
25. Lee S, Malhotra B, Creanga D et al. A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol. 2009; 9: 55.
26. Kaplan SA, McCammon K, Fincher R et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2009; 182(6): 2825-30.
27. Khullar V, Amarenco G, Angulo JC et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013; 63(2): 283-95.
28. Nitti VW, Auerbach S, Martin N et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013; 189(4): 1388-95.
2. Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014; 33(5): 622-4.
3. Coyne KS, Sexton CC, Vats V et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011; 77: 1081.
4. Irwin DE, Kopp ZS, Agatep B et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011; 108: 1132.
5. Chapple CR, Dvorak V, Radziszewski P et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013; 24(9): 1447-58.
6. Chapple C. Systematic review of therapy for men with overactive bladder. Can Urol Assoc J. 2011; 5(suppl 2): S143-5.
7. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016; 43: 289.
8. Fourcade RO, Lacoin F, Roupret M et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol. 2012; 30: 419.
9. McVary KT, Roehrborn CG, Avins AL et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185: 1793.
10. Kaplan SA, Roehrborn CG, Dmochowski R et al. Tolterodine extended release improves over- active bladder symptoms in men with overactive bladder and nocturia. Urology. 2006; 68: 328.
11. Chancellor MB, Zinner N, Whitmore K et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther. 2008; 30: 1766.
12. van Kerrebroeck P, Chapple C, Drogendijk T et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013; 64: 1003.
13. Chapple C, Herschorn S, Abrams P et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with a-blockers. Eur Urol. 2009; 56: 534.
14. Chapple CR, Khullar V, Gabriel Z et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008; 54: 543.
15. Kakizaki H, Lee KS, Yamamoto O et al. Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH). Eur Urol Focus. 2019; 6(4): P729-37.https://doi.org/10.1016/j.euf.2019.10.019.
16. Roehrborn CG. Chapter 103: Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History. In: Wein AJ, Kavoussi LR, Partin AW et al (ed). Campbell and Walsh Urology, 11th Edition. Elsevier-Saunders, Philadephia, PA: 2435.
17. Levin RM, Monson FC, Haugaard N et al. Genetic and cellular characteristics of bladder outlet obstruction. Urol Clin North Am. 1995; 22: 263-83.
18. Levin RM, Haugaard N, O’Connor L et al. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn. 2000; 19: 609-29.
19. Nordling J. The aging bladder – a significant but underestimated role in the development of lower urinary tract symptoms. Exp Gerontol. 2002; 37: 991-9.
20. Chai TC, Andersson KE, Tuttle JB et al. Altered neural control of micturition in the aged f344 rat. Urol Res. 2000; 28: 348-54.
21. Van Venrooj GE, Van Melick HH, Eckhardt MD et al. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol. 2002; 168: 605-9.
22. Wada N, Iuchi H, Kita M et al. Urodynamic efficacy and safety of mirabegron add-on treatment with tamsulosin for Japanese male patients with overactive bladder. Low Urin Tract Symptoms. 2016; 8: 171-6.
23. Ichihara K, Masumori N, Fukuta F et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015; 193: 921-6.
24. Yamaguchi O, Kakizaki H, Homma Y et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms – ASSIST, randomized controlled study. Urology. 2011; 78: 126-33.
25. Lee S, Malhotra B, Creanga D et al. A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol. 2009; 9: 55.
26. Kaplan SA, McCammon K, Fincher R et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2009; 182(6): 2825-30.
27. Khullar V, Amarenco G, Angulo JC et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013; 63(2): 283-95.
28. Nitti VW, Auerbach S, Martin N et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013; 189(4): 1388-95.